Oral Vancomycin Prophylaxis

PreclinicalSmall molecule

MMcGill University Health Centre/Research Institute of the McGill University Health Centre

Oral Vancomycin Prophylaxis is one of 9 small molecule programs targeting Clostridioides difficile Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clostridioides Difficile InfectionRecruiting

Clostridioides Difficile InfectionPreclinical

Recruiting

Competition

Competitive Landscape

9 competitors in Clostridioides Difficile Infection

#DrugCompanyPhaseTrials

Vancomycin or Fidaxomicin

SSejtterapia Kozpont Kft.

Phase 3

1 2

EXL01

EExeliom Biosciences

Phase 2

1 3

Dificlir

Merck & Co.

Preclinical

2 4

AZD5148

AstraZeneca

Phase 2

1 5

ZINPLAVA

Merck & Co.

Preclinical

2 6

CMTS0929

TThe Second Hospital of Nanjing Medical University

Phase 1

1 7

Vancomycin (VAN) Treatment

UUniversity Hospital, Montpellier

Preclinical

1 8

Oral Vancomycin Prophylaxis

MMcGill University Health Centre/Research Institute of the McGill University Health Centre

Preclinical

1 9

LMN-201

LLumen Bioscience, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

PreclinicalRecruiting

Clostridioides Difficile Infection

NCT06979609

Clinical

Trials by Indication[1]

Clostridioides difficile Infection1 trial

Secondary Prophylaxis of Recurrent Clostridioides Difficile Infections During Systemic Antibiotics With Vancomycin: A Randomized Controlled Trial

Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Preclinical·NCT06979609·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oral Vancomycin Prophylaxis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oral Vancomycin Prophylaxis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oral Vancomycin Prophylaxis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — McGill University Health Centre/Research Institute of the McGill University Health Centre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMcGill University Health Centre/Research Institute of the McGill University Health Centre

Oral Vancomycin Prophylaxis

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Clostridioides difficile Infection1 trial

References

Drug Info

Quick Facts

Related News